In this special deep-dive episode of the 2 Minute Medicine® Podcast, we explore the remarkable evolution of GLP-1 receptor agonists from injectable diabetes therapies to some of the most influential drugs in modern medicine. We review the landmark clinical trials behind semaglutide and tirzepatide that transformed expectations for medical weight loss. The episode then examines the emerging race toward oral GLP-1 medications, including Novo Nordisk’s high-dose oral semaglutide and Eli Lilly’s small-molecule orforglipron. Finally, we look ahead to the next generation of metabolic therapies that may soon make once-daily pills the standard for obesity and diabetes care.